GeneDx Holdings Corp. - Class A (WGS) Covered Calls

GeneDx Holdings Corp. is a leader in genomic analysis, delivering personalized health insights that improve outcomes for patients with rare and complex diseases. The company specializes in whole exome and genome sequencing, leveraging its GeneDx Infinity platform—the world’s largest rare disease genomic dataset. By combining clinical expertise with advanced AI, GeneDx provides fast and actionable diagnoses for pediatric and adult patients globally.

You can sell covered calls on GeneDx Holdings Corp. - Class A to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for WGS (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

GeneDx Holdings Corp. (WGS) is an AI-driven health intelligence company focused on the $3 billion rare disease and pediatric specialty market. Its primary offerings are ExomeDx and GenomeDx, advanced sequencing tests that analyze the protein-coding regions (exome) or the entire genetic blueprint (genome) of a patient. These tests are the clinical gold standard for diagnosing neurodevelopmental disorders and rare congenital conditions where traditional testing fails.

The company’s competitive advantage is the GeneDx Infinity™ platform, which houses over 600,000 clinical exomes. In 2026, GeneDx has fully integrated generative AI into this dataset to automate variant interpretation, reducing diagnostic turnaround times to under two weeks. This efficiency has led to a significant "mix-shift" toward high-margin whole genome testing, which now represents the majority of its core revenue. Additionally, the company partners with biopharma firms to accelerate drug discovery for rare diseases using its deep phenotypic and genotypic data.

Competitive Landscape

The genomic testing market is consolidating around high-precision providers. GeneDx competes by maintaining a high "realized price" per test and superior gross margins compared to broad-market laboratories. While it faces competition from diversified diagnostic giants, its focus on the "pediatric odyssey"—the long search for a diagnosis in children—gives it a dominant position in neonatal intensive care units (NICUs) and pediatric neurology clinics.

Key competitors and peers in the genomic and diagnostics space include:

1. Natera, Inc. (NTRA): A major rival in the cell-free DNA and personalized genetic testing market, though more focused on oncology and prenatal screening.
2. Guardant Health, Inc. (GH): A leader in liquid biopsy that competes for clinical testing volume in the advanced diagnostics sector.
3. Illumina, Inc. (ILMN): The sequencing hardware provider that also offers clinical interpretation tools.
4. Hims & Hers Health, Inc. (HIMS): While in a different sub-sector, it is a liquid, optionable health-tech peer often compared for its digital-first growth model.

Strategic Outlook and Innovation

In 2026, GeneDx is on the verge of its first full year of GAAP profitability, driven by a 30% increase in exome and genome testing volumes. The company is strategically expanding into "newborn screening," advocating for whole-genome sequencing to become the standard of care for all infants at birth. This initiative, supported by landmark studies showing average cost savings of $80,000 per child in avoided medical procedures, is a key long-term growth driver.

Innovation at GeneDx is currently focused on "Multi-Omics," integrating RNA sequencing and proteomic data with its existing DNA dataset to provide even higher diagnostic yields. By maintaining its status as an optionable, high-growth stock with a market cap exceeding $1.7 billion, WGS remains a primary target for investors looking to play the "precision medicine" theme. Its shift from a high-burn startup to an efficient, AI-powered diagnostic engine marks its 2026 strategic maturity.

Want more examples? WGO Covered Calls | WH Covered Calls